Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study

(2012) Patrick M. O'Neil et al.   Obesity

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

(2011) W Timothy Garvey et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Evaluation of the Abuse Potential of Lorcaserin, a Serotonin 2C (5-HT2C) Receptor Agonist, in Recreational Polydrug Users

(2011) M J Shram et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

(2011) Meredith C. Fidler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Lorcaserin, a 5-HT2C Agonist, Decreases Nicotine Self-Administration in Female Rats

(2011) E. D. Levin et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

The 5-HT2C Receptor Agonist Lorcaserin Reduces Nicotine Self-Administration, Discrimination and Reinstatement: Relationship to Feeding Behavior and Impulse Control

(2011) Guy A Higgins et al.   NEUROPSYCHOPHARMACOLOGY

Pharmacologic Therapies for Obesity

(2010) Lee M. Kaplan   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure

(2010) Corby K. Martin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization

(2008) W. J. Thomsen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Lorcaserin (APD356), a Selective 5-HT2CAgonist, Reduces Body Weight in Obese Men and Women

(2008) Steven R. Smith et al.   Obesity

Discovery and Structure−Activity Relationship of (1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a Selective Serotonin 5-HT2CReceptor Agonist for the Treatment of Obesity

(2007) Brian M. Smith et al.   JOURNAL OF MEDICINAL CHEMISTRY